People and partners

PharmaFutures 3 was centred around two workshops – in London and Mumbai – at which the Working Group explored current challenges and opportunities to better aligning business value with societal need.

PharmaFutures 3 was a solutions-focused, structured dialogue convened by the pension fund founders of the PharmaFutures series – APG and USS. Central to the project was a Working Group comprised of representatives from the pension funds, pharmaceutical companies, industry analysts, global health experts, social entrepreneurs and emerging markets experts.

Below is a list of the participating organizations and their representatives.

Working group members

  • Dr. Shereen El-Feki, Journalist and Writer,
  • Jeanne-Marie Gescher, OBE, Founder and CEO, Clayton Gescher Associates (cga)
  • Turan Shah, Head (Asia), Mehta Partners
  • Bart Zeldenrust, Senior Portfolio Manager, All Pensions Group (APG)
  • Erik Jan Stork, Sustainability Specialist, All Pensions Group (APG)
  • Matthew Clark, Americas Portfolio Manager, Universities Superannuation Scheme
  • Natasha Landell-Mills, Research Analyst, Responsible Investments, Universities Superannuation Scheme
  • Dr. Daniel Summerfield, Co-Head of Responsible Investment, Universities Superannuation Scheme
  • Abbas Hussain, President for the Emerging Markets, GlaxoSmithKline (GSK)
  • Zito Sartarelli, Company Group Chairman, Johnson & Johnson – Pharmaceuticals Group
  • Dr. Ruud Dobber, Regional Vice President, AstraZeneca Asia Pacific
  • Dr. Jesus Acebillo, Head of Region Emergin Growth Markets and Country Head, Novartis
  • G.V. Prasad, CEO, Dr. Reddys Laboratories Ltd
  • Rema Rajeswaran, Associate, Generation Investment
  • Stewart Adkins, Director, Stweart Adkins Advisors Limited Global Health Experts and Social Entrepreneurs
  • Dr. Hannah E. Kettler, Program Officer, Global Health Policy and Finance, Bill and Melinda Gates Foundation
  • Ruth Levine, Vice President, Programs and Operations, Centre of Global Development
  • David Green, Social Entrepreneur
  • R.D. Thulasiraj, Executive Director, Aravind
  • Dr. Christopher J. Elias, President, PATH
  • Pamela Hartigan, Co-Founder, Volans Ventures

Project team (sustainability)

  • Sophia Tickell, Project Director
  • Alexa Clay, Research Analyst
  • Preetum Shenoy, Research Analyst
  • Ivana Gazibara, Research Analyst
  • Maggie Brenneke, Director, Health Care Client Services

Download

Download PharmaFutures 3

Comments

The industry’s social contract is under severe strain. There is an urgent need for new treatments for antibiotics and diseases like Alzheimer’s. It is in the interest of patients, healthcare providers, industry and pension holders to work together to create the best model for bringing new drugs to market.

Sophia Tickell, Director, PharmaFutures